Norepinephrine

證據等級: L5

預測適應症: 3 個

Norepinephrine: From Unspecified Original Indication to Obstructive Lung Disease

One-Sentence Summary

The original indication and mechanism of action for norepinephrine are not documented in this evidence pack (data gap). The TxGNN model predicts a possible association with Obstructive Lung Disease, but this is currently supported only by indirect, mechanism-level evidence — 0 clinical trials directly test norepinephrine as a treatment for this condition, and the supporting literature largely describes catecholamine physiology in COPD/asthma rather than therapeutic efficacy.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (data gap)
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.84%
Evidence Level	L4 (mechanism/observational only)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for norepinephrine is not available in this evidence pack. Based on general pharmacological knowledge reflected in the supporting literature, norepinephrine is an endogenous catecholamine that acts as an agonist at α/β-adrenergic receptors, and sympathetic/noradrenergic tone is known to modulate airway smooth muscle and vascular caliber (e.g., PMID 2048831, PMID 21271508).

However, the repurposing rationale explicitly flags this as an indirect, physiological association rather than a therapeutic hypothesis. Norepinephrine is clinically used as a systemic vasopressor for shock and hypotension, not as an inhaled or targeted airway therapy. The clinical trials returned for this candidate mostly involve norepinephrine incidentally, as a standard-of-care vasopressor in ECMO, perioperative, or ICU contexts — not as an intervention being tested for obstructive lung disease. The literature evidence instead describes elevated plasma noradrenaline levels and autonomic dysregulation as features of COPD/asthma pathophysiology, which is a correlative finding, not evidence of therapeutic benefit.

Given this, the high TxGNN score likely reflects strong knowledge-graph connectivity between norepinephrine and respiratory-disease nodes (due to extensive co-occurrence in critical-care and physiology literature) rather than a validated treatment signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01219738	N/A	Completed	20	Acute airway vascular smooth muscle response to inhaled budesonide; discusses non-genomic enhancement of endogenous norepinephrine effects at adrenergic receptors — mechanistic relevance, not a norepinephrine intervention trial
NCT02360865	N/A	Completed	18	Mechanisms of exercise intolerance in COPD; explores endothelial function and possible sympathetic/catecholamine involvement
NCT05664204	N/A	Recruiting	200	Intraoperative ECMO strategy in lung transplantation; norepinephrine used only as routine vasopressor support
NCT07022210	N/A	Recruiting	100	Incidence of post-anesthesia hypotension; no direct link to obstructive lung disease
NCT07332442	Phase 3	Not yet recruiting	250	CPAP and arousal threshold in obstructive sleep apnea; norepinephrine not an intervention
NCT02966665	Phase 1	Recruiting	420	Vascular function/exercise rehabilitation in hypertension; not a lung-disease treatment study
NCT02627378	Phase 1	Completed	35	ECMO support for MERS-induced respiratory failure; norepinephrine used only as standard vasopressor
NCT06361420	N/A	Recruiting	43	Lung-protective ventilation strategy in aortic dissection surgery; unrelated to obstructive lung disease treatment
NCT02564406	N/A	Completed	35	Extracorporeal CO2 removal in hypercapnic COPD exacerbation patients who refused intubation; non-pharmacological intervention
NCT04280497	N/A	Recruiting	1800	RCT on corticosteroid therapy in sepsis; norepinephrine mentioned only as a vasopressor endpoint component

Note: None of the above trials test norepinephrine as a treatment for obstructive lung disease; relevance grading (mostly “C”, two “B”) reflects incidental/mechanistic association only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9009625	1996	Cohort	Monaldi Arch Chest Dis	Elevated plasma noradrenaline and altered hemodynamic hormone levels in COPD patients
2048831	1991	Review	Am Rev Respir Dis	Autonomic (noradrenergic/cholinergic) control of airway caliber in asthma and COPD
1617386	1992	Review	Br Med Bull	Sympathetic (noradrenaline) constriction of tracheobronchial vasculature in asthma
35870527	2022	Cohort	Environ Pollut	Air-pollution-associated neuroendocrine (SAM axis) stress hormone changes in COPD vs. non-COPD panel
6777857	1980	Unclassified	Scand J Clin Lab Invest	Increased plasma noradrenaline in COPD, correlated with hemodynamics and blood gases
21271508	2011	Unclassified	Pneumologie	Review of airway innervation (including noradrenergic fibers) in asthma and COPD
29030339	2018	Unclassified	Am J Physiol Heart Circ Physiol	α-adrenergic responsiveness and functional sympatholysis during exercise in COPD
11099681	2000	Unclassified	Am J Med	Mechanisms of hypertension in COPD with acute respiratory failure, including norepinephrine’s role
3332227	1987	Unclassified	Crit Care Clin	Overview of catecholamines (norepinephrine, epinephrine, dopamine) in critical illness
3420304	1988	Unclassified	Respiration	Hemodynamic effects of dopamine/L-dopa in pulmonary hypertension secondary to COLD

Note: No RCTs were identified; all evidence is observational or mechanistic/review in nature, consistent with the L4 evidence level.

US Market Information

No regulatory license records are available in the evidence pack — taiwan_regulatory.licenses is empty and market_status is reported as Not Marketed (0 NDAs on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for norepinephrine in obstructive lung disease consists entirely of mechanistic and observational studies describing catecholamine physiology in COPD/asthma, not therapeutic trials. No clinical trial directly tests norepinephrine as an intervention for this indication, and the evidence pack’s own rationale explicitly characterizes the mechanistic link as correlative co-occurrence rather than causal support. The other two TxGNN-predicted indications (respiratory malformation, Rienhoff syndrome) have even weaker support (L5, no or near-no clinical/literature evidence) and are separately flagged as Hold.

To proceed, the following is needed:

Original indication and mechanism of action (MOA) data for norepinephrine (currently a data gap)
TFDA/US label warnings and contraindications — flagged as a Blocking data gap (DG001); required before any S1 safety pre-assessment
Confirmed DrugBank-sourced MOA — flagged as High severity data gap (DG002)
A dedicated preclinical or mechanistic study directly testing norepinephrine’s effect on airway obstruction (rather than its role as a vasopressor in unrelated critical-care settings)
Regulatory/marketing status confirmation, since no NDA or license record currently exists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.